Early identification of patients with a NAFLD activity score ≥4 and significant fibrosis (≥F2) is crucial, as these individuals are at increased risk for disease progression and may...
Corrie Berk,
DNP, MBA, APRN
Nurse Practitioner, Texas Liver Institute
Top Therapies for Reducing Hepatic Fat in MASH Identified in Meta-Analysis
Metabolic dysfunction–associated steatohepatitis (MASH) is a major contributor to liver disease, and reducing hepatic fat is critical for improving patient...
MASLD: A Growing Global Health Concern Driven by Obesity, Diabetes, and Cardiovascular Risks
The terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been replaced by metabolic-dysfunction-associated steatotic liver disease (MASLD)...
Rezdiffra and Noncirrhotic Non-alcoholic Steatohepatitis
The first US Food and Drug Administration-approved medication to treat noncirrhotic non-alcoholic steatohepatitis, otherwise known as NASH, is Rezdiffra (resmetirom)....
